go to contents

Aposcience AG

Back to list

Facts

Founded
2008
Staff
13
Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health

Profile

Aposcience AG is unique in having developed a secretome-based regenerative therapy. The secretome is produced under GMP-conditions and was approved by the Austrian regulatory agency for a clinical phase II trial. Our product platform Aposec consists of two products: APO-1 - Aposec for internal diseases (acute myocardial infarction, spinal cord injury and stroke) APO-2 - Aposec for topical application (hard-healing wounds, diabetic ulcers)

R&D:Aposcience AG is currently conducting a clinical phase I/II trial for allogeneic APO-2 (ClinicalTrials.gov Identifier: NCT04277598 ). Autologous APO-2 has already been clinically evaluated in a phase I trial (ClinicalTrials.gov Identifier: NCT 02284360) If you are interested in our publications, consult www.aposcience.com --> News --> Key Publications

Similar companies in RDM biotech/pharma

F2G Biotech GmbH

Organization type
RDM biotech/pharma
Region
Vienna
Focus
human health / animal health
Details

Marinomed Biotech AG

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health
Details

ENSEMO GmbH

Organization type
RDM biotech/pharma
Region
Lower Austria
Details

enGenes Biotech GmbH

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
industrial processing
Details

Contact

Dresdner Strasse 87/21
1200 Wien
Vienna

Contact:
Email: info@aposcience.com
Website